Summary by Moomoo AI
T2 Biosystems announced the termination of its Equity Distribution Agreement with Canaccord Genuity LLC on July 19, 2024. The agreement, originally established on March 31, 2021, had enabled the company to sell shares of its common stock through an "at the market" equity offering program with Canaccord acting as sales agent.The company confirmed that no termination penalties are associated with ending the agreement. The termination was executed in accordance with the terms outlined in the original agreement, which was previously filed as Exhibit 1.2 to the Company's Registration Statement on Form S-3 with the SEC on March 31, 2021.
